Search

Your search keyword '"Ziętek, Marcin"' showing total 189 results

Search Constraints

Start Over You searched for: Author "Ziętek, Marcin" Remove constraint Author: "Ziętek, Marcin"
189 results on '"Ziętek, Marcin"'

Search Results

2. Pulsed electric field induces exocytosis and overexpression of MAGE antigens in melanoma

4. Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma

9. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice

10. Post-treatment surveillance principles for selected skin cancers-recommendations of the Surveillance Standardization Section of the Polish Oncology Society.

13. Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report

22. The Current Treatment Trends and Survival Patterns in Melanoma Patients with Positive Sentinel Lymph Node Biopsy (SLNB): A Multicenter Nationwide Study

23. Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment

28. Incidence of different types of cancer in the follow-up period after primary diagnosis and treatment of melanoma. Single-centre 4-year follow-up on a population of 709 patients.

31. Expert recommendation on diagnostic-therapeutic management in skin carcinomas

33. Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients

34. Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence

35. Recommendations of the Polish Sarcoma Group on diagnostic-therapeutic procedures and control in patients with type 1 neurofibromatosis (NF1) and the associated malignant neoplasm of peripheral nerve sheaths

39. Survival of patients with stage IIIC and IIID melanomas with nodal metastases in the light of new therapies

43. Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma

45. Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma.

47. First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland

Catalog

Books, media, physical & digital resources